Aravive (ARAV) Reports Positive Data Supporting Relationship Between AVB-500 Levels, Anti-Tumor Activity and Progression Free Survival in Women with Ovarian Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. MU
6. FDX
7. IBM
8. PRIM
9. PFE
10. ACN

Go back to Aravive (ARAV) Reports Positive Data Supporting Relationship Between AVB-500 Levels, Anti-Tumor Activity and Progression Free Survival in Women with Ovarian Cancer

Aravive Inc. (ARAV) PT Raised to $31 at H.C. Wainwright

November 20, 2019 12:14 PM EST

H.C. Wainwright analyst Joseph Pantginis raised the price target on Aravive Inc. (NASDAQ: ARAV) to $31.00 (from $18.00) while maintaining a Buy rating.

The analyst commented, "This morning, Aravive announced new positive data from the ongoing Phase 1b portion of the Phase 1b/2 clinical trial of... More

Aravive Inc. (ARAV) Halted on LUDP

November 20, 2019 9:46 AM EST

Aravive Inc. (NASDAQ: ARAV) Halted on LUDP

... More

Aravive Inc. (ARAV) Extends Gain, Up 250%

November 20, 2019 7:43 AM EST

Aravive Inc. (NASDAQ: ARAV) Extends Gain, Up 250%

... More

Aravive Inc. (ARAV) Climbs 80% After Positive Data from Ongoing Trial of AVB-500 in Ovarian Cancer

November 20, 2019 7:21 AM EST

Aravive Inc. (NASDAQ: ARAV) Climbs 80% After Positive Data from Ongoing Trial of AVB-500 in Ovarian Cancer

... More